We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
28 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EPYZTEK ustekinumab 45 mg/0.5mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EPYZTEK ustekinumab 90 mg/1 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EPYZTEK ustekinumab 5 mg/1 mL solution for intravenous infusion injection vial.
-
Prescription medicine registrationActive ingredients: Ustekinumab.
-
Australian Public Assessment Report (AusPAR)Onbevzi (bevacizumab) is a biosimilar of Avastin. Onbevzi has been approved to treat a range of cancers either as a monotherapy or in combination with other anti-cancer medicines
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONBEVZI bevacizumab 100 mg/4mL concentrated injection for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONBEVZI bevacizumab 400 mg/16mL concentrated injection for intravenous infusion vial.
-
Prescription medicine decision summaryOnbevzi (bevacizumab) is a biosimilar of Avastin. Onbevzi has been approved to treat a range of cancers either as a monotherapy or in combination with other anti-cancer medicines.
-
Prescription medicine registrationActive ingredients: Bevacizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HADLIMA adalimumab 40 mg/0.4 mL solution for injection in pre-filled syringe.